Investors

Investors

The shareholders have been actively engaged in XNK Therapeutics since the start in 2012, each contributing with their unique competence as well as investing their own money. Despite limited equity investments, the company has taken its leading investigational drug candidate, CellProtect, to Phase II. To accelerate the development of CellProtect, XNK Therapeutics has decided to launch a financing round in XNK Therapeutics.

For more information please contact CIO Markus Lagerlöf (markus.lagerlof@xnktherapeutics.com) or CEO Johan Liwing (johan.liwing@xnktherapeutics.com).

An advantage of autologous NK cell therapies over allogeneic NK cells therapies is that they allow the infusion to the patient without the need for lymphodepletion (immunosuppressive treatment). Moreover, repetitive dosing would not encompass any limitation with autologous cells. Administration of autologous NK cells has a high safety profile. Furthermore, autologous NK cells could readily be applied in settings of, e.g., minimal residual disease (MRD) conditions or in maintenance therapy settings where immunosuppressive treatment could not easily be motivated. Autologous NK cells consequently allow for an extension of the therapeutic applications in the NK cell therapy space, beyond what is currently feasible in allogeneic settings. Autologous NK cells have applications in the treatment of hematological malignancies as well as solid tumors.